Methods and mechanism
Pathway explainers and evidence summaries, each with named authorship, review date, primary sources, and a stated evidence tier.
- Retatrutide: 24.2% mean body-weight reduction at week 48
A Phase 2 retatrutide trial reported a 24.2% mean body-weight reduction at week 48 in 338 adults with obesity or overweight plus a weight-related condition, excluding diabetes.
- Triple agonism vs dual agonism
Coskun et al. characterized retatrutide as a triple agonist at glucagon, GIP, and GLP-1 receptors in experimental systems.
- Why most BPC-157 evidence is rodent evidence
Krivic et al. reported BPC-157 findings in a rat tendon-to-bone injury model.
- Fragment vs full-length thymosin β4
Malinda, Goldstein, and Kleinman studied full-length thymosin β4 in endothelial-cell migration assays.
- Peptide COA: method and reported result
FDA analytical-method guidance describes validation as part of reporting an analytical procedure and its performance characteristics.
- How to Read a Peptide COA: A Practical Guide
A step-by-step way to separate sample identity, amount, chromatographic purity, mass-spec signals, verification, and the limits of a laboratory report.
Peptide Test Canada verification portal (report-specific authentication not completed) ↗
- NNMT inhibition and the NAD salvage pathway
Neelakantan et al. reported increased NAD+ and SAM in differentiated adipocytes and reduced adiposity in diet-induced-obese mice.